TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

OVERVIEW OF ACTIVITY
Given the benefits observed with PARP inhibitors for patients with ovarian and breast cancer, investigators were eager to evaluate the potential of these agents in other BRCA-driven cancer types and for patients with other DNA damage repair (DDR) deficiencies. The prevalence of prostate cancer with potentially susceptible genetic alterations such as BRCA1/2 or ATM led to a number of early clinical trials evaluating PARP inhibitor monotherapy for this disease. These efforts revealed significant activity, sparking an eagerness to combine PARP inhibitors with other effective approaches in an attempt to further improve outcomes. Ongoing trials are investigating PARP inhibitors in combination with antiandrogen therapy or immune checkpoint inhibitors.

These important developments have clear implications for patient care, but they have also brought with them many areas of controversy and uncertainty regarding the potential use of PARP inhibition for prostate cancer. This roundtable discussion with 3 leading genitourinary cancer experts aims to inform clinicians of the role of PARP inhibitors in the management of prostate cancer. By providing information on the latest clinical developments in the context of expert perspectives, this activity will assist medical oncologists with the formulation of evidence-based strategies, which in turn will facilitate optimal patient care.

LEARNING OBJECTIVES

• Comprehend how DDR pathway alterations can be targeted with PARP inhibition in patients with prostate cancer.
• Recognize the frequency with which germline and somatic BRCA1/2 and other DDR mutations are found in patients with prostate cancer, and develop a rational clinical algorithm to guide the use of genetic testing.
• Appreciate available clinical trial data and ongoing research with PARP inhibitors as monotherapy or in combination with androgen receptor-targeted therapy for appropriately selected patients with prostate cancer, and consider the potential role of these strategies in clinical care.
• Recognize the side effects associated with PARP inhibitors for prostate cancer, and develop strategies to prevent, mitigate and manage toxicities.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
This CME activity consists of an audio component.
CME credit is no longer available for this issue

This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute Presidential Endowed Chair in Cancer Research
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah

Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Immunomedics Inc, Janssen Biotech Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Nektar, NewLink Genetics, Novartis, Pfizer Inc, Prometheus Laboratories Inc, Rexahn Pharmaceuticals Inc, Sanofi Genzyme, Takeda Oncology, TRACON Pharmaceuticals Inc.

Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Consulting Agreements: Amgen Inc, Astellas, Clovis Oncology, Dendreon Pharmaceuticals Inc, ESSA Pharma Inc, Janssen Biotech Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Other Remunerated Activities: Licensed patented technology to QIAGEN.

A Oliver Sartor, MD
CE and Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, TeneoBio Inc; Contracted Research: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Innocrin Pharmaceuticals Inc, Invitae, Janssen Biotech Inc, Merck, Progenics Pharmaceuticals Inc, Sanofi Genzyme, SOTIO LLC.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Pfizer Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: April 2020
Expiration date: April 2021